Note: Descriptions are shown in the official language in which they were submitted.
WO 2021/191203
PCT/EP2021/057425
SELF-TESTING FOR NEGATIVE PRESSURE WOUND THERAPY DEVICES
Technical Field
Embodiments described herein relate to apparatuses, systems, and methods for
the
treatment of wounds, for example using dressings in combination with negative
pressure
wound therapy.
Description of the Related Art
Many different types of wound dressings are known for aiding in the healing
process
of a human or animal. These different types of wound dressings include many
different types
of materials and layers, for example, gauze, pads, foam pads or multi-layer
wound dressings.
Topical negative pressure (TNP) therapy, sometimes referred to as vacuum
assisted closure,
negative pressure wound therapy, or reduced pressure wound therapy, is widely
recognized as
a beneficial mechanism for improving the healing rate of a wound. Such therapy
is applicable
to a broad range of wounds such as incisional wounds, open wounds, and
abdominal wounds
or the like. TNP therapy assists in the closure and healing of wounds by
reducing tissue
edema, encouraging blood flow, stimulating the formation of granulation
tissue, removing
excess exudates and may reduce bacterial load. Thus, reducing infection to the
wound.
Furthermore, TNP therapy permits less outside disturbance of the wound and
promotes more
rapid healing.
SUMIVIARY
A negative pressure wound therapy device can include a negative pressure
source
configured to be connected, via a fluid flow path, to a wound covered by a
wound dressing
and provide negative pressure to a wound. The device can include a valve
positioned in the
fluid flow path. The valve can be configured to, in an open state, permit
supply of negative
pressure from the negative pressure source upstream of the valve. The valve
can be
configured to, in a closed state, block supply of negative pressure from the
negative pressure
source upstream of the valve. The device can include a flow restrictor
positioned in the fluid
flow path, which can be positioned downstream of the valve. The device can
include a
pressure sensor configured to measure pressure in the fluid flow path and a
pressure
-1 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
differential across the flow restrictor. The device can include control
circuitry configured to,
in a normal operational mode in which negative pressure is provided to the
wound, cause the
valve to be in the open state. The control circuitry can be configured to, in
a test mode in
which performance of the device is being verified, perform at least one of a
leak test, a flow
test, or an excessive pressure test. The leak test can include the control
circuitry being
configured to cause the valve to be closed, cause the negative pressure source
to operate at a
first intensity level, cause the negative pressure source to pause operation
for a duration of
time, and indicate presence of a leak in the fluid flow path in response to
determining that a
change in the negative pressure measured by the pressure sensor subsequent to
expiration of
the duration of time satisfies a threshold indicative of a leak. The flow test
can include the
control circuitry being configured to cause the valve to be opened, cause the
negative pressure
source to operate at a second intensity level, and indicate insufficient flow
in response to
determining that a pressure differential across the flow restrictor measured
by the pressure
sensor satisfies a pressure differential threshold indicative of insufficient
flow. The excessive
pressure test can include the control circuitry being configured to cause the
valve to be closed,
cause the negative pressure source operate at a third intensity level, and
indicate fault in a
system configured to protect against unsafe negative pressure in the fluid
flow path in
response to determining that pressure in the fluid flow path satisfies a
threshold indicative of
unsafe negative pressure and the system configured to protect against unsafe
negative
pressure has not been activated.
The negative pressure wound therapy device of any of the preceding paragraphs
and/or any of the devices, apparatuses, or systems disclosed herein can
include one or more of
the following features. The second intensity level can be greater than the
first intensity level.
The first intensity level can be equal to the third intensity level. The valve
can be a solenoid
valve. The pressure sensor can include a first pressure sensor positioned
upstream of the flow
restrictor and a second pressure sensor positioned downstream of the flow
restrictor. The
device can include a canister configured to be positioned in the fluid flow
path and collect
fluid aspirated from the wound. The control circuitry can be configured to, in
the test mode,
verify that the canister has been removed from the fluid flow path. The
control circuitry can
be configured to, in the test mode, not perform the leak test, the flow test,
and the excessive
-2-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
pressure test in response to a determination that the canister has not been
removed and that
the wound dressing has not been disconnected. Control can be configured to, in
the test
mode, provide an indication of at least one of that the canister has not been
removed or that
the wound dressing has not been disconnected.
The negative pressure wound therapy device of any of the preceding paragraphs
and/or any of the devices, apparatuses, or systems disclosed herein can
include one or more of
the following features. The system configured to protect against unsafe
negative pressure in
the fluid flow path can include at least one of another valve positioned in
the fluid flow path,
the control circuitry configured to cause the another valve to open responsive
to the pressure
in the fluid flow path satisfying the threshold indicative of unsafe negative
pressure or the
control circuitry being configured to deactivate the negative pressure source
responsive to the
pressure in the fluid flow path satisfying the threshold indicative of unsafe
negative pressure.
The excessive pressure test can include the control circuitry being configured
to indicate fault
in the system configured to protect against unsafe negative pressure in the
fluid flow path in
response to determining the system configured to protect against unsafe
negative pressure has
been activated when pressure in the fluid flow path does not satisfy the
threshold indicative of
unsafe negative pressure. The device can include a check valve positioned in
the fluid flow
path. The check valve can be configured to permit fluid flow downstream toward
the negative
pressure source or an exhaust and prevent fluid flow in the opposite
direction.
The negative pressure wound therapy device of any of the preceding paragraphs
and/or any of the devices, apparatuses, or systems disclosed herein can
include one or more of
the following features. The control circuitry can be configured to perform, in
the test mode, a
health test including determining efficiency of the negative pressure source
and indicating
sufficient health in response to determining that the efficiency satisfies an
efficiency threshold.
The control circuitry can be configured to determine the efficiency of the
negative pressure
source by determining a ratio of an amount of power output by the negative
pressure source
to an amount of power provided to the negative pressure source. The control
circuitry can be
configured to determine the amount of power output by the negative pressure
source based on
determining a product of a mass flow rate and a specific work of the negative
pressure source.
The control circuitry can be configured to determine at least one of the mass
flow rate or the
-3 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
specific work based on determining the pressure differential across the flow
restrictor. The
control circuitry can be configured to determine the mass flow rate based on
determining a
volumetric flow rate. The control circuitry can be configured to perform the
health test
following a successful completion of the flow test The valve can operate as
the flow
restrictor.
A negative pressure wound therapy device can include a negative pressure
source
configured to be connected, via a fluid flow path, to a wound covered by a
wound dressing
and provide negative pressure to a wound. The device can include a valve
positioned in the
fluid flow path. The valve can be configured to, in an open state, permit
supply of negative
pressure from the negative pressure source upstream of the valve. The valve
can be
configured to, in a closed state, block supply of negative pressure from the
negative pressure
source upstream of the valve. The device can include a flow restrictor
positioned in the fluid
flow path. The device can include a pressure sensor configured to measure
pressure in the
fluid flow path. The device can include control circuitry configured to, in a
normal
operational mode in which negative pressure is provided to the wound, cause
the valve to be
in the open state. The control circuitry can be configured to, in a test mode
in which
performance of the device is being verified, perform at least one of a leak
test or a flow test.
The leak test can include the control circuitry being configured to cause the
valve to be
closed, cause the negative pressure source to operate at a first intensity
level, cause the
negative pressure source to pause operation for a duration of time, and
indicate presence of a
leak in the fluid flow path in response to determining that a change in the
negative pressure
measured by the pressure sensor subsequent to expiration of the duration of
time satisfies a
threshold indicative of a leak. The flow test can include the control
circuitry being configured
to: cause the valve to be opened, cause the negative pressure source to
operate at a second
intensity level, and indicate insufficient flow in response to determining
that a pressure
difference across the flow restrictor measured by the pressure sensor
satisfies a pressure
difference threshold indicative of insufficient flow.
The negative pressure wound therapy device of any of the preceding paragraphs
and/or any of the devices, apparatuses, or systems disclosed herein can
include one or more of
the following features. The control circuitry can be configured to, in the
test mode, perform
-4-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
at least one of the leak test, the flow test, or an excessive pressure test.
The excessive
pressure test can include the control circuitry being configured to cause the
valve to be closed,
cause the negative pressure source operate at a third intensity level, and
indicate fault in
excessive pressure protection in response to determining that pressure in the
fluid flow path
satisfies a threshold indicative of unsafe negative pressure and the excessive
pressure
protection has not been activated. The excessive pressure protection can
include at least one
of another valve positioned in the fluid flow path, the control circuitry
configured to cause the
another valve to open responsive to the pressure in the fluid flow path
satisfying the threshold
indicative of unsafe negative pressure (to vent excessive pressure into the
surrounding
environment) or the control circuitry being configured to deactivate the
negative pressure
source responsive to the pressure in the fluid flow path satisfying the
threshold indicative of
unsafe negative pressure. The excessive pressure test can include the control
circuitry being
configured to indicate fault in the excessive pressure protection in response
to determining the
excessive pressure protection has been activated when pressure in the fluid
flow path does not
satisfy the threshold indicative of unsafe negative pressure.
The negative pressure wound therapy device of any of the preceding paragraphs
and/or any of the devices, apparatuses, or systems disclosed herein can
include one or more of
the following features. The second intensity level can be greater than the
first intensity level.
The valve can be a solenoid valve. The pressure sensor can include a first
pressure sensor
positioned upstream of the flow restrictor and a second pressure sensor
positioned
downstream of the flow restrictor. The device can include a canister
configured to be
positioned in the fluid flow path and collect fluid aspirated from the wound.
The control
circuitry can be configured to, in the test mode, verify that the canister has
been removed from
the fluid flow path. The control circuitry can be configured to, in the test
mode, not perform
the leak test and the flow test in response to a determination that the
canister has not been
removed and that the wound dressing has not been disconnected. The control
circuitry can be
configured to, in the test mode, provide an indication of at least one of that
the canister has
not been removed or that the wound dressing has not been disconnected. The
device can
include a check valve positioned in the fluid flow path. The check valve can
be configured to
-5 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
permit fluid flow downstream toward the negative pressure source or an exhaust
and prevent
fluid flow in the opposite direction.
The negative pressure wound therapy device of any of the preceding paragraphs
and/or any of the devices, apparatuses, or systems disclosed herein can
include one or more of
the following features. The control circuitry can be configured to perform, in
the test mode, a
health test comprising determining efficiency of the negative pressure source
and indicating
sufficient health in response to determining that the efficiency satisfies an
efficiency threshold.
The control circuitry can be configured to determine the efficiency of the
negative pressure
source by determining a ratio of an amount of power output by the negative
pressure source
to an amount of power provided to the negative pressure source. The control
circuitry can be
configured to determine the amount of power output by the negative pressure
source based on
determining a product of a mass flow rate and a specific work of the negative
pressure source.
The control circuitry can be configured to determine at least one of the mass
flow rate or the
specific work based on determining the pressure difference across the flow
restrictor. The
control circuitry is configured to determine the mass flow rate based on
determining a
volumetric flow rate. The control circuitry can be configured to perform the
health test
following a successful completion of the flow test. The valve can operate as
the flow
restrictor.
Disclosed are methods of operating a negative pressure wound therapy device of
any
of the preceding paragraphs and/or any of the devices, apparatuses, or systems
disclosed
herein. Discloses are kits that include the negative pressure wound therapy
device of any of
the preceding paragraphs and/or any of the devices, apparatuses, or systems
disclosed herein
and one or more wound dressings or canisters.
Any of the features, components, or details of any of the arrangements or
embodiments disclosed in this application, including without limitation any of
the apparatus
embodiments and any of the negative pressure wound therapy embodiments
disclosed herein,
are interchangeably combinable with any other features, components, or details
of any of the
arrangements or embodiments disclosed herein to form new arrangements and
embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
-6-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
Figure lA illustrates a negative pressure wound therapy system.
Figure 1B illustrates another negative pressure wound therapy system.
Figure 2A is an isometric view of a negative pressure wound therapy device and
canister, showing the canister detached from the pump assembly of the device.
Figure 2B is a back view of the negative pressure wound therapy device shown
in
Figure 2A.
Figure 2C illustrates a top surface of the negative pressure wound therapy
device
shown in Figure 2A, showing a user interface.
Figure 3 illustrates a schematic of a control system of a negative pressure
wound
therapy device.
Figure 4 illustrates another negative pressure wound therapy system.
Figure 5 illustrates a negative pressure wound therapy device configured to
perform
self-testing.
Figures 6 to 9 illustrate flow charts of tests that can be performed by the
negative
pressure wound therapy device of Figure 5.
Figure 10 illustrates a manifold that can be utilized by the negative pressure
wound
therapy device of Figure 5.
Figure 11 illustrates a graph of several tests being performed by the negative
pressure
wound therapy device of Figure 5.
DETAILED DESCRIPTION
Embodiments disclosed herein relate to systems and methods of treating and/or
monitoring a wound. Some embodiments of the negative pressure wound therapy
devices
disclosed herein can include a negative pressure source configured to be
connected and/or
fluidically coupled, via a fluid flow path, to a wound covered by a wound
dressing and provide
negative pressure to a wound.
Throughout this specification reference is made to a wound. The term wound is
to be
broadly construed and encompasses open and closed wounds in which skin is
torn, cut or
punctured or where trauma causes a contusion, or any other superficial or
other conditions or
imperfections on the skin of a patient or otherwise that benefit from pressure
treatment. A
-7-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
wound is thus broadly defined as any damaged region of tissue where fluid may
or may not be
produced. Examples of such wounds include, but are not limited to, abdominal
wounds or
other large or incisional wounds, either as a result of surgery, trauma,
sterniotomies,
fasciotomies, or other conditions, dehisced wounds, acute wounds, chronic
wounds, subacute
and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations,
abrasions,
contusions, bums, diabetic ulcers, pressure ulcers, stoma, surgical wounds,
trauma and venous
ulcers or the like.
Embodiments of systems and methods disclosed herein can be used with topical
negative pressure ("TNP") or reduced pressure therapy systems. Briefly,
negative pressure
wound therapy assists in the closure and healing of many forms of "hard to
heal" wounds by
reducing tissue oedema, encouraging blood flow and granular tissue formation,
or removing
excess exudate and can reduce bacterial load (and thus infection risk). In
addition, the therapy
allows for less disturbance of a wound leading to more rapid healing. TNP
therapy systems
can also assist in the healing of surgically closed wounds by removing fluid.
TNP therapy can
help to stabilize the tissue in the apposed position of closure. A further
beneficial use of TNP
therapy can be found in grafts and flaps where removal of excess fluid is
important and close
proximity of the graft to tissue is required in order to ensure tissue
viability.
As used herein, reduced or negative pressure levels, such as ¨X mmHg,
represent
pressure levels relative to normal ambient atmospheric pressure, which can
correspond to 760
mmHg (or 1 atm, 29.93 thug, 101.325 kPa, 14.696 psi, etc.). Accordingly, a
negative
pressure value of ¨X mmHg reflects pressure that is X mmHg below 760 mmHg or,
in other
words, a pressure of (760¨X) mmHg. In addition, negative pressure that is
"less" or "smaller"
than X mmHg corresponds to pressure that is closer to atmospheric pressure
(for example, ¨
40 rrunHg is less than ¨60 mmHg). Negative pressure that is "more" or
"greater" than ¨X
mmHg corresponds to pressure that is further from atmospheric pressure (for
example, ¨80
mmHg is more than ¨60 mmHg). In some cases, local ambient atmospheric pressure
is used
as a reference point, and such local atmospheric pressure may not necessarily
be, for example,
760 mmHg.
Systems and methods disclosed herein can be used with other types of treatment
in
addition to or instead of reduced pressure therapy, such as irrigation,
ultrasound, heat or cold,
-8-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
neuro stimulation, or the like. In some cases, disclosed systems and methods
can be used for
wound monitoring without application of additional therapy. Systems and
methods disclosed
herein can be used in conjunction with a dressing, including with compression
dressing,
reduced pressure dressing, or the like.
A healthcare provider, such as a clinician, nurse, or the like, can provide a
TNP
prescription specifying, for example, the pressure level or time of
application. However, the
healing process is different for each patient and the prescription may affect
the healing process
in a way the clinician or healthcare provider did not expect at the time of
devising the
prescription. A healthcare provider may try to adjust the prescription as the
wound heals (or
does not heal), but such process may require various appointments that can be
time
consuming and repetitive. Embodiments disclosed herein provide systems,
devices, or
methods of efficiently adjusting TNP prescriptions and delivering effective
'TNT' therapy.
Wound Therapy System
Figure 1A schematically illustrates a negative pressure wound treatment system
100
(sometimes referred to as a reduced or negative pressure wound therapy system,
a TNP
system, or a wound treatment system). In any implementations disclosed herein,
though not
required, the negative pressure wound treatment system 100 can include a wound
filler 102
placed on or inside a wound 104 (which may be a cavity). The wound 104 can be
sealed by a
wound cover 106, which can be a drape, such that the wound cover 106 can be in
fluidic
communication with the wound 104. The wound filler 102 in combination with the
wound
cover 106 can be referred to as a wound dressing. A tube or conduit 108 (also
referred to
herein as a flexible suction adapter or a fluidic connector) can be used to
connect the wound
cover 106 with a wound therapy device 110 (sometimes as a whole or partially
referred to as a
pump assembly") configured to supply reduced or negative pressure. The conduit
108 can
be a single or multi lumen tube. A connector 112 can be used to removably and
selectively
couple a conduit or tube 142 with the conduit 108.
In any of the systems disclosed herein, a wound therapy device can be
canisterless,
wherein, for example and without limitation, wound exudate is collected in the
wound
-9-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
dressing or is transferred via a conduit for collection at another location
However, any of the
wound therapy devices disclosed herein can include or support a canister.
Additionally, with any of the wound therapy systems disclosed herein, any of
the
wound therapy devices can be mounted to or supported by the wound dressing or
adjacent to
the wound dressing. The wound filler 102 can be any suitable type, such as
hydrophilic or
hydrophobic foam, gauze, inflatable bag, and so on. The wound filler 102 can
be conformable
to the wound 104 such that the wound filler 102 substantially fills the cavity
of the wound
104. The wound cover 106 can provide a substantially fluid impermeable seal
over the wound
104. The wound cover 106 can have a top side and a bottom side. The bottom
side can
adhesively (or in any other suitable manner) seal with the wound 104, for
example by sealing
with the skin around the wound 104. The conduit 108 or any other conduit
disclosed herein
can be formed from polyurethane, PVC, nylon, polyethylene, silicone, or any
other suitable
material.
The wound cover 106 can have a port (not shown) configured to receive an end
of the
conduit 108. In some cases, the conduit 108 can otherwise pass through or
under the wound
cover 106 to supply reduced pressure to the wound 104 so as to maintain a
desired level of
reduced pressure in the wound 104. The conduit 108 can be any suitable article
configured to
provide at least a substantially sealed fluid flow pathway or path between the
wound therapy
device 110 and the wound cover 106, so as to supply the reduced pressure
provided by the
wound therapy device 110 to wound 104.
The wound cover 106 and the wound filler 102 can be provided as a single
article or
an integrated single unit. In some cases, no wound filler is provided and the
wound cover by
itself may be considered the wound dressing. The wound dressing can then be
connected, via
the conduit 108, to a source of negative pressure of the wound therapy device
110. In some
cases, though not required, the wound therapy device 110 can be miniaturized
and portable,
although larger conventional negative pressure sources (or pumps) can also be
used.
The wound cover 106 can be located over a wound site to be treated. The wound
cover 106 can form a substantially sealed cavity or enclosure over the wound.
The wound
cover 106 can have a film having a high water vapour permeability to enable
the evaporation
of surplus fluid, and can have a superabsorbing material contained therein to
safely absorb
-10-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
wound exudate. In some cases, the components of the TNP systems described
herein can be
particularly suited for incisional wounds that exude a small amount of wound
exudate.
The wound therapy device 110 can operate with or without the use of an exudate
canister.
In some cases, as is illustrated, the wound therapy device 110 can
include an
exudate canister. In some cases, configuring the wound therapy device 110 and
conduit 108
so that the conduit 108 can be quickly and easily removed from the wound
therapy device 110
can facilitate or improve the process of wound dressing or pump changes, if
necessary. Any
of the pump assemblies disclosed herein can have any suitable connection
between the conduit
108 and the pump.
The wound therapy device 110 can deliver negative pressure of approximately -
80
mmHg, or between about -20 mmHg and -200 mmHg. Note that these pressures are
relative
to normal ambient atmospheric pressure thus, -200 mmHg would be about 560 mmHg
in
practical terms. In some cases, the pressure range can be between about -40
mmHg and -150
mmHg. Alternatively, a pressure range of up to -75 mmHg, up to -80 mmHg or
over -80
mmHg can be used. Also in some cases a pressure range of below -75 mmHg can be
used.
Alternatively, a pressure range of over approximately -100 mmHg, or even -150
mmHg, can
be supplied by the wound therapy device 110.
As will be described in greater detail below, the negative pressure wound
treatment
system 100 can be configured to provide a connection 332 to a separate or
remote computing
device 334. The connection 332 can be wired or wireless (such as, Bluetooth,
NEC, WiFi, or
cellular). The remote computing device 334 can be a smartphone, a tablet, a
laptop or
another standalone computer, a server (such as, a cloud server), another pump
device, or the
like.
Figure 1B illustrates another negative pressure wound treatment system 100'.
The
negative pressure wound treatment system 100' can have any of the components,
features, or
other details of any of the other negative pressure wound treatment system
disclosed herein,
including without limitation the negative pressure wound treatment system 100
illustrated in
Figure 1A or the negative pressure wound treatment system 400 illustrated in
Figure 4, in
combination with or in place of any of the components, features, or other
details of the
negative pressure wound treatment system 100' shown in Figure 1B and/or
described herein.
-11 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
The negative pressure wound treatment system 100' can have a wound cover 106
over a
wound 104 that can seal the wound 104. A conduit 108', such as a single or
multi lumen tube
can be used to connect the wound cover 106 with a wound therapy device 110'
(sometimes as
a whole or partially referred to as a "pump assembly") configured to supply
reduced or
negative pressure. The wound cover 106 can be in fluidic communication with
the wound
104.
With reference to Figure 1B, the conduit 108' can have a bridge portion 130
that can
have a proximal end portion and a distal end portion (the distal end portion
being closer to the
wound 104 than the proximal end portion, and an applicator 132 at the distal
end of the bridge
portion 130 forming the flexible suction adapter (or conduit) 108'. A
connector 134 can be
disposed at the proximal end of the bridge portion 130, so as to connect to at
least one of the
channels that can extend along a length of the bridge portion 130 of the
conduit 108 shown in
Figure 1B. A cap 140 can be coupled with a portion of the conduit 108 and can,
in some
cases, as illustrated, be attached to the connector 134. The cap 140 can be
useful in
preventing fluids from leaking out of the proximal end of the bridge portion
130. The conduit
108' can be a Soft Port manufactured by Smith & Nephew. As mentioned, the
negative
pressure wound treatment system 100' can include a source of negative
pressure, such as the
device 110', capable of supplying negative pressure to the wound 104 through
the conduit
108'. Though not required, the device 110' can also include a canister or
other container for
the storage of wound exudates and other fluids that can be removed from the
wound.
The device 110' can be connected to the connector 134 via a conduit or tube
142. In
use, the applicator 132 can be placed over an aperture formed in a cover 106
that is placed
over a suitably-prepared wound or wound 104. Subsequently, with the wound
therapy device
110' connected via the tube 142 to the connector 134, the wound therapy device
110' can be
activated to supply negative pressure to the wound. Application of negative
pressure can be
applied until a desired level of healing of the wound is achieved.
The bridge portion 130 can comprise an upper channel material or layer
positioned
between an upper layer and an intermediate layer, with a lower channel
material or layer
positioned between the intermediate layer and a bottom layer. The upper,
intermediate, and
lower layers can have elongate portions extending between proximal and distal
ends and can
-12-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
include a material that is fluid-impermeable, for example polymers such as
polyurethane. It
will of course be appreciated that the upper, intermediate, and lower layers
can each be
constructed from different materials, including semi-permeable materials. In
some cases, one
or more of the upper, intermediate, and lower layers can be at least partially
transparent In
some instances, the upper and lower layers can be curved, rounded or outwardly
convex over
a majority of their lengths.
The upper and lower channel layers can be elongate layers extending from the
proximal end to the distal end of the bridge 130 and can each preferably
comprise a porous
material, including for example open-celled foams such as polyethylene or
polyurethane. In
some cases, one or more of the upper and lower channel layers can be comprised
of a fabric,
for example a knitted or woven spacer fabric (such as a knitted polyester 3D
fabric, Baltex
7970®, or Gehring 879®) or a nonwoven material, or terry-woven or loop-
pile
materials. The fibers may not necessarily be woven, and can include felted and
flocked
(including materials such as Flotex®) fibrous materials. The materials
selected are
preferably suited to channeling wound exudate away from the wound and for
transmitting
negative pressure or vented air to the wound site, and can also confer a
degree of kinking or
occlusion resistance to the channel layers. In one example, the upper channel
layer can
include an open-celled foam such as polyurethane, and the lower channel layer
can include a
fabric. In another example, the upper channel layer is optional, and the
system can instead be
provided with an open upper channel. The upper channel layer can have a
curved, rounded or
upwardly convex upper surface and a substantially flat lower surface, and the
lower channel
layer can have a curved, rounded or downwardly convex lower surface and a
substantially flat
upper surface.
The fabric or material of any components of the bridge 130 can have a three-
dimensional (3D) structure, where one or more types of fibers form a structure
where the
fibers extend in all three dimensions. Such a fabric can in some cases aid in
wicking,
transporting fluid or transmitting negative pressure. In some cases, the
fabric or materials of
the channels can include several layers of material stacked or layered over
each other, which
can in some cases be useful in preventing the channel from collapsing under
the application of
negative pressure. The materials used in some implementations of the conduit
108' can be
-13 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
conformable and pliable, which can, in some cases, help to avoid pressure
ulcers and other
complications which can result from a wound treatment system being pressed
against the skin
of a patient.
The distal ends of the upper, intermediate, and lower layers and the channel
layers can
be enlarged at their distal ends (to be placed over a wound site), and can
form a "teardrop" or
other enlarged shape. The distal ends of at least the upper, intermediate, and
lower layers and
the channel layers can also be provided with at least one through aperture.
This aperture can
be useful not only for the drainage of wound exudate and for applying negative
pressure to the
wound, but also during manufacturing of the device, as these apertures can be
used to align
these respective layers appropriately.
In some implementations, a controlled gas leak 146 (sometimes referred to as
gas leak,
air leak, or controlled air leak) can be disposed on the bridge portion 130,
for example at the
proximal end thereof This air leak 146 can comprise an opening or channel
extending
through the upper layer of the bridge portion 130, such that the air leak 146
is in fluidic
communication with the upper channel of the bridge portion 130. Upon the
application of
suction to the conduit 108, gas (such, as air) can enter through the gas leak
146 and move
from the proximal end of the bridge portion 130 to the distal end of the
bridge portion along
the upper channel of the bridge portion 130. The gas can then be suctioned
into the lower
channel of the bridge portion 130 by passing through the apertures through the
distal ends of
the upper, intermediate, and lower layers.
The air leak 146 can include a filter. Preferably, the air leak 146 is located
at the
proximal end of the bridge portion 130 so as to minimize the likelihood of
wound exudate or
other fluids coming into contact and possibly occluding or interfering with
the air leak 146 or
the filter. In some instances, the filter can be a microporous membrane
capable of excluding
microorganisms and bacteria, and which may be able to filter out particles
larger than 45 um.
Preferably, the filter can exclude particles larger than 1.0 um, and more
preferably, particles
larger than 0.2 um. Advantageously, some implementations can provide for a
filter that is at
least partially chemically-resistant, for example to water, common household
liquids such as
shampoos, and other surfactants. In some cases, reapplication of vacuum to the
suction
adapter or wiping of the exposed outer portion of the filter may be sufficient
to clear any
-14-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
foreign substance occluding the filter. The filter can be composed of a
suitably-resistant
polymer such as acrylic, polyethersulfone, or polytetrafluoroethylene, and can
be oleophobic
or hydrophobic. In some cases, the gas leak 146 can supply a relatively
constant gas flow that
does not appreciably increase as additional negative pressure is applied to
the conduit 108'.
In instances of the negative pressure wound treatment system 100 where the gas
flow through
the gas leak 146 increases as additional negative pressure is applied,
preferably this increased
gas flow will be minimized and not increase in proportion to the negative
pressure applied
thereto. Further description of such bridges, conduits, air leaks,
and other components,
features, and details that can be used with any implementations of the
negative pressure
wound treatment systems disclosed herein are found in U.S. Patent No.
8,801,685, which is
incorporated by reference in its entirety as if fully set forth herein.
Any of the wound therapy devices (such as, the device 110 or 110') disclosed
herein
can provide continuous or intermittent negative pressure therapy. Continuous
therapy can be
delivered at above 0 mmHg, -25 mmHg, -40 mmHg, -50 mmHg, -60 mmHg, -70 mmHg, -
80
mmHg, -90 mmHg, -100 mmHg, -120 mmHg, -140 mmHg, -160 mmHg, -180 mmHg, -200
mmHg, or below -200 mmHg. Intermittent therapy can be delivered between low
and high
negative pressure set points (sometimes referred to as setpoint). Low set
point can be set at
above 0 mmHg, -25 mmHg, -40 mmHg, -50 mmHg, -60 mmHg, -70 mmHg, -80 mmHg, -90
mmHg, -100 mmHg, -120 mmHg, -140 mmHg, -160 mmHg, -180 mmHg, or below -180
mmHg. High set point can be set at above -25 mmHg, -40 mmHg, -50 mmHg, -60
mmHg,
-70 mmHg, -80 mmHg, -90 mmHg, -100 mmHg, -120 mmHg, -125 mmHg, -140 mmHg,
-160 mmHg, -180 mmHg, -200 mmHg, or below -200 mmHg. During intermittent
therapy,
negative pressure at low set point can be delivered for a first time duration,
and upon
expiration of the first time duration, negative pressure at high set point can
be delivered for a
second time duration. Upon expiration of the second time duration, negative
pressure at low
set point can be delivered. The first and second time durations can be same or
different
values.
In operation, the wound filler 102 can be inserted into the cavity of the
wound 104,
and wound cover 106 can be placed so as to seal the wound 104. The wound
therapy device
110' can provide negative pressure to the wound cover 106, which can be
transmitted to the
-15-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
wound 104 via the wound filler 102. Fluid (such as, wound exudate) can be
drawn through
the conduit 108' and stored in a canister. In some cases, fluid is absorbed by
the wound filler
102 or one or more absorbent layers (not shown).
Wound dressings that can be utilized with the pump assembly and systems of the
present application include Renasys-F, Renasys-G, Renasys AB, and Pico
Dressings available
from Smith & Nephew. Further description of such wound dressings and other
components
of a negative pressure wound therapy system that can be used with the pump
assembly and
systems of the present application are found in U.S. Patent Publication Nos.
2012/0116334,
2011/0213287, 2011/0282309, 2012/0136325, U.S. Patent No. 9,084,845, and
International
App. No. PCT/EP2020/078376, each of which is incorporated by reference in its
entirety as if
fully set forth herein. In some cases, other suitable wound dressings can be
utilized.
Figures 2A-2C show the negative pressure wound therapy device 110'. As
illustrated,
a pump assembly 160 and canister 162 can be connected, thereby forming the
wound therapy
device 110'. With reference to Figure 2C, the pump assembly 160 can include an
interface
panel 170 having a display 172, one or more indicators 174, or one or more
controls or
buttons, including, for example and without limitation, a therapy start and
pause button 180 or
an alarm/alert mute button 182. The interface panel 170 can have one or more
input controls
or buttons 184 (three being shown) that can be used to control any functions
of the pump
assembly 160 or the interface panel 170. For example and without limitation,
one or more of
the buttons 184 can be used to turn the pump assembly 160 on or off, to start
or pause
therapy, to operate and monitor the operation of the pump assembly 160, to
scroll through
menus displayed on the display 172, or to control or perform other functions.
In some cases,
the command buttons 184 can be programmable, and can be made from a tactile,
soft rubber.
Additionally, the interface panel 170 can have visual indicators 186 that can
indicate
which of the one or more buttons 184 is active. The interface panel 170 can
also have a
lock/unlock control or button 188 that can be configured to selectively lock
or unlock the
functionality of the various buttons (e.g., buttons 184) or the display 172.
When the
lock/unlock button 188 is in the locked state, depressing one or more of the
various other
buttons or the display will not cause the pump assembly 160 to change any
display functions
or performance functions of the device. This way, the interface panel 170 will
be protected
-16-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
from inadvertent bumping or touching of the various buttons or display. The
interface panel
170 can be located on an upper portion of the pump assembly 160, for example
and without
limitation on an upward facing surface of the pump assembly 160.
The display 172, which can be a screen such as an LED screen, can be mounted
in a
middle portion of the interface panel 170. The display 172 can be a touch
screen display. The
display 172 can support playback of audiovisual (AV) content, such as
instructional videos,
and render a number of screens or graphical user interfaces (GUIs) for
configuring,
controlling, and monitoring the operation of the pump assembly 160.
The one or more indicators 174 can be lights (such as, LEDs) and can be
configured to
provide a visual indication of alarm conditions and or a status of the pump.
For example and
without limitation, the one or more indicators 174 can be configured to
provide a visual
indication of a status of the pump assembly 160 or other components of the
negative pressure
wound treatment system 100', including without limitation the conduit 108' or
the wound
cover 106 (such as, to provide an indication of normal operation, low battery,
a leak, canister
full, blockage, overpressure, or the like). Any one or more suitable
indicators can be
additionally or alternatively used, such as visual, audio, tactile indicator,
and so on.
Figure 2B shows a back or rear view of the wound therapy device 110' shown in
the
Figure 2A. As shown, the pump assembly 160 can include a speaker 192 for
producing
sound. For example and without limitation, the speaker 192 can generate an
acoustic alarm in
response to deviations in therapy delivery, non-compliance with therapy
delivery, or any other
similar or suitable conditions or combinations thereof The speaker 192 can
provide audio to
accompany one or more instructional videos that can be displayed on the
display 172.
The pump assembly 160 can be configured to provide easy access (such as, an
access
door on the casing of the pump assembly) to one or more filters of the pump
assembly 160,
such as antibacterial filters. This can enable a user (such as, a healthcare
provider or patient)
to more easily access, inspect or replace such filters. The pump assembly 160
can also include
a power jack 196 for providing power to the pump assembly 160 or for charging
and
recharging an internal power source (such as, a battery). Some implementations
of the pump
assembly 160 can include a disposable or renewable power source, such as one
or more
-17-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
batteries, so that no power jack is needed. The pump assembly 160 can have a
recess 198
formed therein to facilitate gripping of the pump assembly 160.
The canister 162 can hold fluid aspirated from the wound 104. For example, the
canister 162 can have an 800 mL (or approximately 800 mL) capacity, or from a
300 mL or
less capacity to a 1000 mL or more capacity, or any capacity level in this
range. The canister
162 can include a tubing for connecting to the conduit 108' in order to form a
fluid flow path.
The canister 162 can be replaced with another canister, such as when the
canister 162 has
been filled with fluid. With reference to Figure 2A, the wound therapy device
110' can
include a canister inlet tube 200 (also referred to herein as a dressing port
connector) in fluid
communication with the canister 162. For example and without limitation, the
canister inlet
tube 200 can be used to connect with the conduit 108'.
The canister 162 can be selectively coupleable and removable from the pump
assembly
160. With reference to Figure 2A, in some cases, a canister release button 202
can be
configured to selectively release the canister 162 from the pump assembly 160.
With
reference to Figure 2B, the canister 162 can have one or more fill lines or
graduations 204 to
indicate to the user and amount of fluid or exudate stored within the canister
162.
The wound therapy device 110' can have a handle 208 that can be used to lift
or carry
the wound therapy device 110'. The handle 208 can be coupled with the pump
assembly 160
and can be rotatable relative to the wound therapy device 110' so that the
handle can be
rotated upward for lifting or carrying the wound therapy device 110' or the
pump assembly
160, or rotated into a lower profile in a more compact position when the
handle is not being
used. In some cases, the handle 208 can be coupled with the pump assembly 160
in a fixed
position. The handle 208 can be coupled with an upper portion of the pump
assembly 160 or
can be removable from the wound therapy device 110'.
Figure 3 illustrates a schematic of a control system 300 that can be employed
in any of
the wound therapy devices described herein, such as in the wound therapy
device 110'.
Electrical components can operate to accept user input, provide output to the
user, operate
the pressure source, provide connectivity, and so on. A first processor (such
as, a main
controller 310) can be responsible for user activity, and a second processor
(such as, a pump
controller 370) can be responsible for controlling another device, such as a
pump 390.
-18-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
An input/output (I/0) module 320 can be used to control an input and/or output
to
another component or device, such as the pump 390, one or more sensors (for
example, one
or more pressure sensors 325 configured to monitor pressure in one or more
locations of the
fluid flow path), or the like. For example, the I/O module can receive data
from one or more
sensors through one or more ports, such as serial (for example, I2C),
parallel, hybrid ports,
and the like. Any of the pressure sensors can be part of the wound therapy
device or the
canister. In some cases, any of the pressure sensors 325 can be remote to the
wound therapy
device, such as positioned at or near the wound (for example, in the dressing
or the conduit
connecting the dressing to the wound therapy device). In such implementations,
any of the
remote pressure sensors can communicate with the I/0 module over a wired
connection or
with one or more transceivers 340 over a wireless connection.
The main controller 310 can receive data from and provide data to one or more
expansion modules 360, such as one or more USB ports, SD ports, Compact Disc
(CD)
drives, DVD drives, FireWire ports, Thunderbolt ports, PCI Express ports, and
the like. The
main controller 310, along with other controllers or processors, can store
data in memory 350
(such as one or more memory modules), which can be internal or external to the
main
controller 310. Any suitable type of memory can be used, including volatile or
non-volatile
memory, such as RAM, ROM, magnetic memory, solid-state memory,
Magnetoresistive
random-access memory (MRAM), and the like.
The main controller 310 can be a general purpose controller, such as a low-
power
processor or an application specific processor. The main controller 310 can be
configured as
a "central" processor in the electronic architecture of the control system
300, and the main
controller 310 can coordinate the activity of other processors, such as the
pump controller
370, communications controller 330, and one or more additional processors 380.
The main
controller 310 can run a suitable operating system, such as a Linux, Windows
CE, VxWorks,
etc.
The pump controller 370 can control the operation of a pump 390, which can
generate
negative or reduced pressure. The pump 390 can be a suitable pump, such as a
diaphragm
pump, peristaltic pump, rotary pump, rotary vane pump, scroll pump, screw
pump, liquid ring
pump, diaphragm pump operated by a piezoelectric transducer, voice coil pump,
and the like.
-19-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
The pump controller 370 can measure pressure in a fluid flow path, using data
received from
one or more pressure sensors 325, calculate the rate of fluid flow, and
control the pump. The
pump controller 370 can control the pump actuator (such as, a motor) so that a
desired level
of negative pressure is achieved in the wound 104. The desired level of
negative pressure can
be pressure set or selected by the user. The pump controller 370 can control
the pump (for
example, pump motor) using pulse-width modulation (PWM) or pulsed control. A
control
signal for driving the pump can be a 0-100% duty cycle PWM signal. The pump
controller
370 can perform flow rate calculations and detect alarms. The pump controller
370 can
communicate information to the main controller 310. The pump controller 370
can be a low-
power processor.
A communications controller 330 can provide connectivity (such as, a wired or
wireless connection 332). The communications controller 330 can utilize one or
more
transceivers 340 for sending and receiving data. The one or more transceivers
340 can
include one or more antennas, optical sensors, optical transmitters, vibration
motors or
transducers, vibration sensors, acoustic sensors, ultrasound sensors, or the
like. The
communications controller 330 can provide one or more of the following types
of
connections: Global Positioning System (GPS), cellular connectivity (for
example, 2G, 3G,
LTE, 4G, 5G, or the like), near field communication (NFC), Bluetooth
connectivity, radio
frequency identification (RFID), wireless local area network (WLAN), wireless
personal area
network (WPAN), WiFi connectivity, Internet connectivity, optical connectivity
(for example,
using infrared light, barcodes, such as QR codes, etc.), acoustic
connectivity, ultrasound
connectivity, or the like. Connectivity can be used for various activities,
such as pump
assembly location tracking, asset tracking, compliance monitoring, remote
selection,
uploading of logs, alarms, and other operational data, and adjustment of
therapy settings,
upgrading of software or firmware, pairing, and the like.
The communications controller 330 can provide dual GPS/cellular functionality.
Cellular functionality can, for example, be 3G, 4G, or 5G functionality. The
communications
controller 330 can communicate information to the main controller 310. The
communications
controller 330 can include internal memory or can utilize memory 350. The
communications
controller 330 can be a low-power processor.
-20-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
The control system 300 can store data, such as GPS data, therapy data, device
data,
and event data. This data can be stored, for example, in memory 350. This data
can include
patient data collected by one or more sensors. The control system 300 can
track and log
therapy and other operational data. Such data can be stored, for example, in
the memory 350.
Using the connectivity provided by the communications controller 330, the
control
system 300 can upload any of the data stored, maintained, or tracked by the
control system
300 to a remote computing device, such as the device 334. The control system
300 can also
download various operational data, such as therapy selection and parameters,
firmware and
software patches and upgrades, and the like (for example, via the connection
to the device
334). The one or more additional processors 380, such as processor for
controlling one or
more user interfaces (such as, one or more displays), can be utilized. In some
cases, any of
the illustrated or described components of the control system 300 can be
omitted depending
on an embodiment of a wound monitoring or treatment system in which the
control system
300 is used.
Any of the negative pressure wound therapy devices described herein can
include one
or more features disclosed in U.S. Patent No. 9,737,649 or U.S. Patent
Publication No.
2017/0216501, each of which is incorporated by reference in its entirety.
Multiple Dressing Negative Wound Therapy
Figure 4 illustrates another negative pressure wound treatment system 400. The
system 400 can include a wound therapy device capable of supplying negative
pressure to the
wound site or sites, such as wound therapy device 110'. The wound therapy
device 110' can
be in fluidic communication with one or more wound dressings 406a, 406b
(collectively
referred to as 406) so as to supply negative pressure to one or more wounds,
such as the
wounds 104a and 104b. A first fluid flow path can include components providing
fluidic
connection from the wound therapy device 110' to the first wound dressing
406a. As a non-
limiting example, the first fluid flow path can include the path from the
wound dressing 406a
to the wound therapy device 110' or the path from the first wound dressing
406a to an inlet
446 of a branching attachment (or connector) 444 in fluidic connection with
the wound
-21-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
therapy device 110'. Similarly, a second fluid flow path can include
components providing
fluidic connection from the wound therapy device 110' to the second wound
dressing 406b.
The system 400 can be similar to the system 100' with the exception that
multiple
wounds 104a and 140b are being treated by the system 400_ The system 400 can
include any
one or more of the components of the system 100', which are illustrated in
Figure 4 with
appended letter "a" or "b" to distinguish between the first and second wounds
(such as, the
wounds 104a and 104b, the covers 106a and 106b). As illustrated, the system
400 can include
a plurality of wound dressings 406a, 406b (and corresponding fluid flow paths)
in fluidic
communication with the wound therapy device 110' via a plurality of suction
adapters, such as
the adapter 108'. The suction adapters can include any one or more of the
components of the
adapter 108', which are illustrated in Figure 4 with appended letter "a" or
"b" to distinguish
between the first and second wounds (such as, the bridge portions 130a and
130b, the
connectors 134a and 134b, and the caps 140a and 140b).
The wound therapy device 110' can be fluidically coupled via the tube 142 with
the
inlet 446 of the connector 444. The connector 444 can be fluidically coupled
via branches
445a, 445b and tubes or conduits 442a, 442b with the connectors 134a, 134b,
which can be
fluidically coupled with the tubes or conduits 130a, 130b. The tubes or
conduits 130a, 130b
can be fluidically coupled with the dressings 406a, 406b. Once all conduits
and dressing
components are coupled and operably positioned, the wound therapy device 110'
can be
activated, thereby supplying negative pressure via the fluid flow paths to the
wounds 430a,
430b. Application of negative pressure can be applied until a desired level of
healing of the
wounds 430 is achieved. Although two wounds and wound dressing are illustrated
in Figure
4, some implementations of the wound therapy device 110' can provide treatment
to a single
wound (for instance, by closing the unused branch 445a or 445b of the
connector 444) or to
more than two wounds (for instance, by adding branches to the connector 444).
The system 400 can include one or more features disclosed in U.S. Patent
Publication
No. 2020/0069850 or International Publication No. W02018/167199, each of which
is
incorporated by reference in its entirety.
-22-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
Self-Testing of Negative Pressure Devices
In some cases, a negative pressure wound therapy device (such as, the device
110)
may need to be tested to ensure that it is capable of providing negative
pressure wound
therapy safely and effectively. Such testing may involve verifying one or more
of: that the
leak rate of the device is within acceptable limits, that the negative
pressure source provides
adequate flow, that an excessive pressure safety system is operational, the
efficiency (or
health) of the negative pressure wound therapy device or the like. The testing
can additionally
or alternatively involve one or more of: prompting the user to press one or
more of the
buttons (such as, the buttons 184) of the user interface to confirm normal
operation, confirm
that the display (such as the display 172) is illuminated, confirm that one or
more of the status
indicators (such as, the status indicators 174) are illuminated, confirm that
the speaker (such
as, the speaker 192) is operational, or the like. The testing may be performed
when the device
is used with a new patient, periodically (such as, semi-annually), or the
like. The testing
parameters, such as the timing and pressure settings, can be varied to
accommodate different
self-test hardware designs. For example, the pressure can be varied from about
-40 mmHg to
about -250 mmHg. Existing devices are typically sent by the user (such as, a
patient or health
care provider (HCP), or the like), to the device manufacturer or a third-party
for testing.
However, this approach is time consuming, expensive, and disruptive.
Figure 5 illustrates a negative pressure wound therapy device 500 configured
to
perform self-testing. Device 500 can include one or more features of any of
the devices
described herein, such as the device 110. Device 500 may be capable of
performing self-
testing in the field without the need to send the device to the manufacturer
or third-party. For
example, the user can cause the device 500 to perform self-testing. Self-
testing can be
activated, for instance, via the user interface of the device, such as via the
display 206. Self-
testing can be initiated remotely. Device 500 can provide an indication to the
user (who may
be local or remote) or a remote computing system that self-testing has
completed successfully
or unsuccessfully. The indication can be provided using any of the approaches
described
herein, such as visually, audibly, tactilely, via remote transmission, or the
like. The indication
can include information regarding which particular test or tests have been
completed
successfully or failed. In some cases, responsive to a determination that self-
testing has
-23 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
completed unsuccessfully, the indication can include disabling provision of
negative pressure
wound therapy.
Device 500 can include an inlet 510, a canister 520 (which can be optional),
and a
negative pressure source (positioned in the direction indicated by the arrow
560). In a
canisterless system, the inlet 510 can be similar to the connector 430
illustrated in Figure 4A.
A one-way valve or check valve 550 can be included to ensure that the fluid
flows
downstream toward the negative pressure source (in the direction indicated by
the arrow 560)
and not in the opposite direction, for example, when the negative pressure
source is
deactivated or stopped. The check valve 550 can stop any reverse flow when the
negative
pressure source is stopped. The device 500 can include a valve 530, a flow
restrictor 540, and
pressure sensors 532 and 534 positioned in the fluid flow path upstream and
downstream of
the flow restrictor 540. In some cases, the pressure sensors 532 and 534 can
be replaced with
a differential pressure sensor configured to measure pressure across the flow
restrictor 540
and pressure in the fluid flow path. The fluid flow path can include the
negative pressure
source and other components that are internal to or integral with the negative
pressure source,
such as one or more connectors, manifolds, lumens, tubes, valves (for example,
one or more
valves of the negative pressure source), or the like. In some implementations,
the flow
restrictor 540 can be a valve, such as a solenoid valve (or solenoid) or a
manually operated
valve. For instance, the valve 530 can also be the flow restrictor. The flow
restriction
produced by the flow restrictor 540 can result in a known pressure drop across
the pressure
measured by the pressure sensors 532 and 534.
During normal operation in which the device 500 provides negative pressure to
a
wound covered by a wound dressing fluidically connected to the inlet 510, the
valve 530 can
remain open. Device 500 can regulate negative pressure in the fluid flow path
based on a
pressure signal from the pressure sensor 532 (and/or the pressure sensor 534).
During self-
testing, the valve 530 can be closed. The valve 530 can be a solenoid valve
opened and closed
by a controller (or one or more controllers) of the device 500 or a manually
operated valve.
Pressure sensors 532 and 534 can be checked during normal operation to verify
that similar
values of pressure are being detected. A limit (or threshold) can be set for
the variation in the
pressure detected by the pressure sensors 532 and 534. Responsive to a
determination that
-24-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
the limit has been satisfied, a determination that self-test has failed can be
made and an
indication can be provided.
Figure 6 illustrates a process 600 for performing self-testing. The process
600 can be
implemented by the device 500, such as performed under control of a controller
(or one or
more controllers) of the device 500. In block 602, the process 600 can verify
that the canister
or wound dressing is disconnected. In some cases, the wound dressing can be
connected to
the canister. The process 600 can verify in block 602 that one or more of the
wound dressing
(for instance, in a canisterless system) or canister (for example, in a system
with a canister)
has been disconnected. This can be performed via one or more of a sensor, such
as, an optical
sensor, electromagnetic sensor (for example, a Hall effect sensors),
electrical switch,
mechanical switch, or the like. In some cases, self-testing can be performed
without removing
the canister. This may provide the benefit of having the canister filter act
as a protection from
particles (such as, dust or debris) entering the system and potentially
causing damage to any of
the components 530, 532, 534, 540, 550, or the negative pressure source.
It may be advantageous to remove one or more of the wound dressing or canister
during self-testing in order to ensure there is no restriction to flow of
fluid, establish a fixed
volume in the fluid flow path subjected to self-testing, or the like. For
example, due to
unknown volume of fluid absorbed by the wound dressing, wound dressing
fluidically
connected to the device 500 can present a substantial restriction to the flow
of fluid, which
can cause inaccurate performance of self-testing. As another example, when the
canister is
present, self-testing may be performed inaccurately to due unknown volume of
fluid that may
be present in the canister (for example, fluid aspirated from the wound). As
yet another
example, safety may be promoted by not performing the excessive pressure test
when the
device is fluidically connected to a patient. In some cases, the process 600
can prompt the
user to remove one or more of the canister or wound dressing. The process 600
can generate
an indication in response to determining in block 602 that one or more of the
wound dressing
or canister has not been removed. The process 600 can terminate self-testing
in response to
determining in block 602 that one or more of the wound dressing or canister
has not been
removed.
-25-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
The process 600 can transition to block 604 in which it can perform a leak
test of the
device. The leak test can be used to verify that the leak rate of the device
is within acceptable
limits for negative pressure wound therapy. If the leak test fails, the
process 600 can
transition to block 614. If the leak test passes, the process 600 can
transition to block 606
and perform a flow test of the device. The flow test can be used to verify
that the negative
pressure source of the device provides adequate flow for negative pressure
wound therapy. If
the flow test fails, the process 600 can transition to block 614. If the flow
test passes, the
process 600 can transition to block 608 and verify that excessive pressure
safety system of the
device is operational. Excessive pressure safety system can prevent
application of unsafe
level(s) of negative pressure to the wound (for example, negative pressure of
about -235
mmHg or less, about -240 mmHg or less or more, about -245 mmHg or less or
more, about -
250 mmHg or more, or the like). In some cases, excessive pressure safety
system can include
a valve or another mechanism that configured to release negative pressure in
response to
detection of excessive negative pressure level(s). For example, a valve can be
opened to
release excess negative pressure to the atmosphere. Excessive pressure safety
system can
alternatively or additionally include deactivating the negative pressure
source or the device
500 in response to detection of excessive negative pressure level(s). If an
excessive pressure
test fails, the process 600 can transition to block 614. If the excessive
pressure test passes,
the process 600 can transition to block 612. In block 612, the process 600 can
provide an
indication that self-testing has completed successfully. In some cases, the
order of the tests
604 to 608 can be different. For example, the flow test in block 606 can be
performed before
the leak test in block 604.
In block 614, the process 600 can provide an indication that self-testing has
not
completed successfully. Such indication can include information about which of
the one or
more tests have not completed successfully, as described herein.
Figure 7 illustrates a process 700 for the leak test. The process 700 can be
performed
in block 604 of Figure 6. The process 700 can be implemented by the device
500, such as
performed under control of a controller (or one or more controllers) of the
device 500. The
process 700 can begin in block 702 in which the valve 530 can be closed. In
block 704, the
process 700 can activate the negative pressure source. The process 700 can
cause the
-26-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
negative pressure source to run at low intensity or low level of activity
(such as, about 10% of
the duty cycle (such as, PWM) or less or more, about 20% of the duty cycle
(such as, PWM)
or less or more, about 30% of the duty cycle or less or more, or the like).
For example, the
process 700 can cause low level of power to be supplied to an actuator (such
as, a motor,
piezoelectric transducer, or the like) of the negative pressure source. The
process 700 can
remain in block 704 until a first threshold level of negative pressure has
been established in the
fluid flow path. This can be verified by the pressure sensor 532 (or pressure
sensor 534). The
first threshold level of negative pressure can be at least about -100 mmHg,
about -150 mmHg
or less or more, about -160 mmHg or less or more, about -170 mmHg or less or
more, about
-180 mmHg or less or more, about -190 mmHg or less or more, about -200 mmHg or
more,
or the like. The first threshold level of negative pressure can be dependent
on various factors,
such as the type of negative pressure source being utilized by the device 500,
type of wounds
that the device 500 is configured to treat (for example, treating large wounds
may necessitate
that the device 500 be configured to provide greater levels of negative
pressure and greater
flow rates than treating small wounds), or the like.
In some cases, after the valve 530 has been closed, the volume of the fluid
flow path
may be quite small. Activating the negative pressure source and deactivating
the negative
pressure source when the first threshold level of negative pressure has been
established (as
may be normally performed during application of negative pressure wound
therapy to a
wound) can cause the negative pressure in the fluid flow path to reach a level
that satisfies
excessive negative pressure level(s). This may undesirably cause the excessive
pressure safety
system to be activated. To avoid such outcome, the actuator of the negative
pressure source
may be activated for a fixed period of time or a fixed duty cycle, after which
pressure in the
fluid flow path can be verified. Subsequently, the actuator can be activated
again if needed to
establish the first threshold level of negative pressure. For example, the
actuator can be a
motor that can be pulsed for a fixed period of time or pulsed for a single
rotation (or multiple
rotations). Subsequently, pressure in the fluid flow path can be verified, and
the motor can be
pulsed again if the first threshold level of negative pressure has not been
established.
The process 700 can transition to block 706 in which it can verify that the
first
threshold level of negative pressure has been established in the fluid flow
path. For example,
-27-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
the process 700 can verify that the pressure sensor 532 reads negative
pressure level that is
greater than (or more negative) or equal to the first threshold level of
negative pressure. If the
verification in block 706 is unsuccessful, the process 700 can transition to
block 714 where it
can provide indication that the leak test has failed. For example, the leak
test can fail due to
presence of one or more leaks in the fluid flow path that prevent the process
700 from
establishing the first threshold level of negative pressure in the fluid flow
path.
If the verification in block 706 is successful, the process 700 can transition
to block
708. In block 708, the process 700 can implement a delay for a threshold
period of time. The
threshold period of time can be, for example, 1 second or less, 2 seconds or
less or more, 5
seconds or less or more, 10 seconds or more, or the like. In block 708, the
negative pressure
source can be deactivated in order to allow negative pressure in the fluid
flow path to
decrease (or become more positive). Such negative pressure decay may be due to
presence of
one or more inherent leaks in the fluid flow path (for example, one or more
connectors,
manifolds, or valves, such as the valve 530, in the fluid flow path may have
an inherent leak).
As described herein, the threshold period of time for the delay can be
dependent on various
factors, such as type of negative pressure source being utilized by the device
500, the type of
wounds that the device 500 is configured to treat, or the like.
After the threshold period of time has elapsed, the process 700 can transition
to block
710 where it can verify that negative pressure decrease in the fluid flow path
satisfies a
pressure decay threshold. Even though one or more inherent leaks may be
present in the fluid
flow path, such leaks should not be too large or severe to cause a large
negative pressure drop
in the fluid flow path during the delay in block 708. The pressure decay
threshold can be set
to a relatively small value, such as 1 mmHg or less, 2 mmHg or less, 3 mmHg or
less, 4
mmHg or less, 5 mmHg or less or more, 10 mmHg or less or more, 20 mmHg or less
or more,
25 mmHg or less or more, or the like. As described herein, the pressure decay
threshold can
be dependent on various factors, such as the type of negative pressure source
being utilized by
the device 500, type of wounds that the device 500 is configured to treat, or
the like. In block
710, the process 700 can utilize readings of the pressure sensor 532 or 534.
If the process 700 verifies in block 710 that the negative pressure in the
fluid flow path
satisfies the pressure decay threshold, the process 700 can transition to
block 712 where it can
-28-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
indicate successful completion of the leak test. For example, in block 710,
the process 700
can verify that negative pressure in the fluid flow path is greater than (or
more negative) or
equal to the difference between the first threshold level of negative pressure
and the pressure
decay threshold. If the verification in block 710 is unsuccessful, the process
700 can transition
to block 714 where it can provide indication that the leak test has failed.
This may be due to
one or more leaks in the flow path causing the pressure decay to be too steep.
Figure 8 illustrates a process 800 for the flow test. The process 800 can be
performed
in block 606 of Figure 6. The process 800 can be implemented by the device
500, such as
performed under control of a controller (or one or more controllers) of the
device 500. The
process 800 can begin in block 802 in which the valve 530 can be opened. In
block 804, the
process 800 can activate the negative pressure source. The process 800 can
cause the
negative pressure source to run at high intensity or maximum level of
activity. For example,
the process 800 can cause maximum level of power to be supplied to the
actuator of the
negative pressure source. In block 804, the process can cause the negative
pressure to run for
a threshold duration of time, such as about 1 second or less, about 2 seconds
or less or more,
about 3 seconds or less or more, about 4 seconds or less or more, about 5
seconds or less or
more, about 6 seconds or less or more, about 7 seconds or less or more, about
8 seconds or
less or more, about 9 seconds or less or more, about 10 seconds or more, or
the like.
Block 804 can be executed to cause the negative pressure source to operate at
highest
or maximum flow (such as, highest or maximum duty cycle (such as, about 95%
PWM or
more)). Because such operation can cause significant increase in negative
pressure in the fluid
flow path, the process 800 can execute block 802 (to open the valve 530) in
order to not
cause the excessive pressure safety system to be activated, as described
herein.
The process 800 can transition block 806 where it can verify that pressure
difference
across the flow restrictor 540 satisfies a pressure difference threshold
indicative of adequate
flow. Flow restrictor 540 can have cross-sectional area that is narrower than
cross-sectional
area of the other components in the fluid flow path. For example, the flow
restrictor 540 can
be one or more of thin, relatively long tube or conduit, a small orifice or
aperture, or the like.
As another example, the flow restrictor 540 can be a variable area flow
restrictor with cross-
sectional area that can be varied or adjusted (for example, by one or more
controllers) so that
-29-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
undue burden is not placed on the negative pressure source to overcome the
flow restriction
caused by the flow restrictor during normal operation. For example, the flow
restrictor 540
can be a butterfly valve, needle valve, ball valve, solenoid valve, or the
like. As yet another
example, a bypass tube or conduit with unrestricted cross-sectional area can
be placed across
the flow restrictor. During normal operation, fluid can flow across the bypass
conduit.
During self-testing, fluid can flow across the flow restrictor 540. Fluid flow
can be directed to
either the bypass conduit or the flow restrictor 540 by using one or more
valves, such as one
or more solenoid valves or the like. Additional details of the flow restrictor
are disclosed in
U.S. Patent Nos. 8,974,429 and 9,636,440, each of which is incorporated by
reference in its
entirety.
As a result of restricting the fluid flow, pressure difference can be created
across the
flow restrictor 540. Such pressure difference can be determined by the
pressure sensors 532
and 534. Pressure difference measurements can be used to determine the flow
rate in the fluid
flow path as the pressure difference can be proportional to the flow rate. For
example, the
pressure difference can be proportional to the flow rate such that increase in
the flow rate can
cause increase in the pressure difference. In some cases, because the valve
530 has been
opened in block 802, the pressure sensor 532 can measure atmospheric pressure.
Pressure
sensor 534 positioned downstream of the flow restrictor 540 can measure more
negative
pressure due to the restriction of flow caused by the flow restrictor. In
block 806, measured
pressure difference can be compared to the pressure difference threshold. The
pressure
difference threshold can be about 5 mmHg or less, 10 mmHg or less or more,
about 15 mmHg
or less or more, about 20 mmHg or more, or the like. The pressure difference
threshold can
be dependent on various factors, such as type of negative pressure source
being utilized by the
device 500, the type of wounds that the device 500 is configured to treat,
flow rate through
the flow path, or the like.
If the process 800 determines that the pressure difference across the flow
restrictor
540 satisfies the pressure difference threshold, it can transition to block
812 where it can
indicate successful completion of the flow test. For example, the process 800
can transition to
block 812 in response to determining that the pressure difference is greater
than or equals the
pressure difference threshold. If the verification in block 806 is
unsuccessful, the process 800
-30-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
can transition to block 814 where it can provide indication that the flow test
has failed. For
example, the process 800 can transition to block 814 in response to
determining that the
pressure difference is smaller than the pressure difference threshold. Failure
of the flow test
may be due to failure of one or more components of the negative pressure
source (such as the
actuator), blockage in the fluid flow path, or the like.
In some cases, after transitioning to block 812, the process 800 can test the
health of
the negative pressure wound therapy device. The device health can be
determined based on
the efficiency of the negative pressure source (such as, the pump). The
efficiency can be
determined as the ratio of power out to power in using Equation 1.
AP
ro ' Out :k [,}U. ;:c spccr lc v% ark
4err*.,
Efficiency (ii) = . = -
Power in r , t
Power in can reflect the power consumed by the negative pressure source. Power
in can be
determined as a product of current and voltage supplied to the negative
pressure source. In
some implementations, the current can be measured and calculated via a sense
resistor and,
optionally, an amplifier. The sense resistor can be placed in series with the
negative pressure
source. The output from the sense resistor (which can be voltage across the
resistor) can be
fed into an amplifier. The amplifier can amplify the voltage, which may be
small due to small
resistance of the resistor. The current provided to the negative pressure
source can be
calculated using Ohm's law (voltage output by the amplifier/resistance of the
resistor).
Power out can be indicative of the actual performance of the negative pressure
source
(such as, power output by the negative pressure source). According to Equation
1, power out
can be calculated via determining mass flow rate and specific work. Mass flow
rate can be
calculated using Equation 4. To determine the mass flow rate, volumetric flow
rate (V) and
density of air (pan) can be utilized. Volumetric flow rate can be indicative
of the volume of
fluid that passes over time. As described herein (such as, in connection with
the block 806),
change in pressure across the flow restrictor 540, which can be measured as
the difference
between the pressure readings by the pressure sensors 532 and 534, can be
indicative of the
volumetric flow rate. In some cases, the flow restrictor 540 can be modeled to
determine the
-31 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
relationship between the flow (or volumetric flow rate) and the change of
pressure. For
example, Bernoulli's equation can be used. In some instances, the relationship
can be linear.
Vofun 7tric flow rate ----- V
(2)
,
Specific work = W = _______________________________________________________
(3)
Van'
Mass flow rate = lvi = pair xuxA = pair XV
(4)
Dens ;'-y of air (5)
Pair
A
In some instances, mass flow rate can be measured directly, such as, by using
a flow
sensor (or flow meter. For instance, a hot wire sensor can be used.
Density of air can change with the temperature and altitude. Equation 5 can be
used
to determine the density at a specific temperature and altitude.
In this equation,
Pabsolute(atmospheric) is the atmospheric pressure (in Pascal), 1-?specific is
the specific gas
constant for dry air (287.058 JIKg-1K-1), and T is the temperature (in
Kelvin). In some cases,
density of air at room temperature (20 degrees Celsius) and mean sea-level
atmospheric
pressure (101.325 kPa) can be used, which equals to 1.2041 kg/ml. According to
Equation 3,
specific work (W) can be determined as the ratio of the pressure difference
(between pressures
measured by the pressure sensors 532 and 534) and density of air. In some
instances, the
pressure difference can be compared to a threshold, which can indirectly
provide the measure
of specific work. For instance, the negative pressure source can be operated
at maximum
intensity (to provide maximum flow) and the pressure difference can be
compared to a
threshold associated with the specific work when maximum flow is being
provided. The
threshold can be adjusted for the density of air, as explained herein. If the
threshold is
satisfied (such as, met or exceeded), a predetermined value of specific work
(associated with
providing maximum flow) can be used for calculating the efficiency.
In block 816, the process can determine the mass flow rate. By determining the
mass
flow rate, efficiency of the negative pressure source can be calculated in a
variety of
temperature and pressure conditions (such as, at different altitudes). In some
cases, an
indication of the mass flow rate can be provided (such as, displayed).
-32-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
The process 800 can transition to block 818, in which the efficiency of the
negative
pressure source can be determined. The efficiency can be calculated using
Equation 1, as
described above. The process 800 can transition to block 820, in which the
efficiency
determined in block 818 can be compared to an efficiency threshold. The
efficiency threshold
can be indicative of the efficiency of the device determined before the
negative pressure
wound therapy device has been put into use. For example, the efficiency
threshold can be
indicative of the efficiency of the device determined at manufacturing. If the
determined
efficiency satisfies the efficiency threshold (such as, equal or within 1%,
2%, 5%, or 10% of
the efficiency threshold), the process can transition to block 822 indicating
the device has
passed the health test. For instance, a diaphragm pump can be about 20%
efficient. The
efficiency threshold can be set at 15% efficiency (or more or less). Not
meeting the efficiency
threshold may signify that the negative pressure source is unable to deliver
negative pressure
wound therapy or is able to do so while producing too much heat. If in block
818 it is
determined that the efficiency does not satisfy the efficiency threshold, the
process 800 can
transition to block 824 indicating the negative pressure wound therapy device
failed the health
test. Health can be determined as a ratio between the efficiency of the device
determined
before the negative pressure wound therapy device has been put into use and
the efficiency
determined in block 818. The determined health value can be provided to the
user, such as
displayed. The process of checking the device health can advantageously allow
the user to
determine the health of the device and whether the device should be serviced
without needing
to send the device into a service and repair center. In some implementations,
the health test
can be performed separately from the flow test.
Figure 9 illustrates a process 900 for the excessive pressure test. The
process 900 can
be performed in block 608 of Figure 6. The process 900 can be implemented by
the device
500, such as performed under control of a controller (or one or more
controllers) of the
device 500. The process 900 can begin in block 902 in which the valve 530 can
be closed. In
block 904, the process 900 can activate the negative pressure source. Similar
to block 704 of
Figure 7, in block 904, the process 900 can cause the negative pressure source
to run at low
intensity or low level of activity. For example, the process 900 can cause low
level of power
-33 -
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
to be supplied to the actuator of the negative pressure source. Same or
different intensity
level or low activity level can be used as in block 704.
The process 900 can remain in block 904 until a second threshold level of
negative
pressure has been established in the fluid flow path. This can be verified by
the pressure
sensor 532 (or pressure sensor 534). The second threshold level of negative
pressure can
correspond to negative pressure that is just less than (or more positive) than
an excess (or
excessive) pressure threshold indicative or unsafe level(s) of negative
pressure (for example,
negative pressure of about -235 mmHg or less, about -240 mmHg or less or more,
about -245
mmHg or less or more, about -250 mmHg or more, or the like). For instance, the
second
threshold level of negative pressure can be about -200 mmHg or less, about -
210 mmHg or
less or more, about -220 mmHg or less or more, about -230 mmHg or less or
more, -250
mmHg or less or more, or the like.
When the second threshold level of negative pressure has been established in
the fluid
flow path, the process 900 can transition to block 906 in which it can verify
that the excessive
pressure safety system has not been activated. Unless there is a fault, the
excessive pressure
safety system should not be activated because negative pressure in the fluid
flow path has not
reached the excess pressure threshold. If such verification fails, the process
900 can transition
to block 914 where it can provide indication that the excessive pressure test
has failed.
If the verification in block 906 is successful, the process 900 can transition
to block
908 and activate the negative pressure source. Block 908 can be similar to
block 904 except
that the process 900 can remain in block 908 (with the negative pressure
source being active)
until the negative pressure level in the fluid flow path satisfies the excess
pressure threshold.
For example, the process 900 can remain in block 908 until negative pressure
in the fluid flow
path reaches or exceeds the excess pressure threshold. This verification can
be performed by
pressure sensor 532 (or pressure sensor 534). Subsequently, the process 900
can transition to
block 910 where it can verify that the excessive pressure safety system has
been activated (for
example, the negative pressure source has been deactivated). In case the
excessive pressure
safety system includes another valve configured to vent excessive pressure
into the
surrounding environment, the process 900 can include activating the negative
pressure source
in block 908 at a different level of intensity (such as, the maximum level of
intensity) to verify
-34-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
that the excess pressure threshold cannot be achieved. For instance, the level
of intensity can
be higher than the one described herein in connection with segment 1130 of
Figure 11. If
such verification fails, the process 900 can transition to block 914. If the
verification in block
910 is successful, the process 900 can transition to block 912 where it can
indicate successful
completion of the excessive pressure test.
In some cases, the process 900 can additionally or alternatively execute the
flow test
of the process 800. If the flow test fails (such as, the process 800 reaching
block 814), it can
be concluded that the excessive pressure safety system has been activated. If
the flow test is
successfully completed (such as, the process 800 reaching block 812), it can
be concluded that
the excessive pressure safety system has not been activated. In some
instances, the flow test
can be executed before transitioning from block 910 to 912. Executing the flow
test can
provide additional or alternative verification regarding activation of the
excessive safety
system.
Figure 10 illustrates a manifold 1000 that can be utilized by the negative
pressure
wound therapy device of Figure 5. The manifold 1000 can incorporate one or
more of a
valve 1030 (which can correspond to the valve 530), pressure sensors 1032 and
1034 (which
can correspond to the pressure sensors 532 and 534), flow restrictor 1090
(which can
correspond to the flow restrictor 540), check valve 1050 (which can correspond
to the check
valve 550), or connections between any of these components. The manifold 100
can include
an electronics board 1072 (for example, circuit board) supporting pressure
sensors 1032 and
1034, which can correspond to the pressure sensors 532 and 534, respectively.
The
electronics board 1072 can support a valve 1030, which can correspond to the
valve 530. The
valve 1030 can be a solenoid valve.
The manifold 1000 can formed from parts or housings 1074 and 1078 separated by
a
membrane or gasket 1076. The gasket 1076 can be designed to provide a fluid-
tight seal
when the housings 1074 and 1078 are connected. The housings 1074 and 1078 can
be glued
together, welded together (for example, using ultrasonic welding), or the
like. The housing
1074 can support the electronics board 1072. The gasket 1076 can support a
check valve
1050, which can correspond to the check valve 550. In some cases, the check
valve 1050 can
be positioned external to the manifold 1000.
-35-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
The housing 1078 can include an inlet 1012, which can be fluidically connected
to a
canister (if present, or to a dressing in a canisterless system) and located
downstream of the
canister. With reference to Figure 5, the inlet 1012 can be positioned on a
side of the canister
520 opposite the inlet 510. The inlet 1012 can be similar to the connector 430
illustrated in
Figure 4A. The housing 1078 can include an outlet 1062, which can be
fluidically connected
to the negative pressure source. The outlet 1062 can be positioned at or near
location
indicated by the arrow 560 in Figure 5. The housing 1078 can include an outlet
1 082
fluidically connected to an exhaust of the negative pressure source. The
housing 1078 can
include a silencer configured to reduce noise, vibration, or the like produced
by the negative
pressure source during operation or one or more filters configured to prevent
one or more of
odor, bacteria, or the like from being released into the surrounding
environment. The housing
1078 can include an outlet 1084 fluidically connected to an exhaust (such as,
external
atmosphere) to expel gas after it has passed through the silencer. In some
cases, the silencer
can be external to the manifold and outlets 1082 and 1084 may be omitted.
Additional details
of the silencer and one or more filters are disclosed in U.S. Patent No.
8,845,603 and U.S.
Patent Publication No. 2018/0318476, each of which is incorporated by
reference in its
entirety.
A flow restrictor 1090, which can correspond to the flow restrictor 540, can
be
integrated into the manifold 1000. For example, the flow restrictor 1090 can
be positioned in
the housing 1074. The flow restrictor can be placed between the inlet 1012 and
the outlet
1062. In some cases, the flow restrictor 1090 can be a solenoid valve. In
cases when the
valve 1030 functions as the flow restrictor, component 1090 can be omitted.
Additional details of the manifold are disclosed in U.S. Patent Nos. 9,084,845
and
9,427,505 and U.S. Patent Publication No. 2018/0318476, each of which is
incorporated by
reference in its entirety.
Use of the manifold 1000 or another modular unit can advantageously allow for
efficient troubleshooting, for instance, in case one or more tests conducted
during self-testing
fail. For example, the manifold 1000 or another modular unit could be replaced
in response to
one or more of the processes 600, 700, 800, or 900 executing one or more of
the blocks 614,
714, 814, or 914. Such design can allow the user to quickly replace one or
more potentially
-36-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
faulty components that may have caused self-testing to fail. The manifold 1000
or another
modular unit can be detachable from the device 500. During repair or service,
removing a
potentially faulty manifold 1000 or another modular unit and attaching a
different manifold
100 or another modular unit to the device 500 can result in successful
completion of self-
testing. In some cases, the negative pressure source can be replaced along
with the manifold
1000 or another modular unit. For example, the negative pressure source can be
attached to
or integrated in the manifold 1000 to form a replaceable modular unit.
Figure 11 illustrates a graphical output 1100 of performing the flow test,
leak test and
excessive pressure test. X-axis can represent time. Y-axis can represent the
pressure and
duty cycle of the negative pressure source. Curve 1102 can represent pressure
in the fluid
flow path (as measured by one or more of the pressure sensors 532 or 534, such
as, the
pressure sensor 534). Curve 11 04 can represent duty cycle of the negative
pressure source.
The flow test is illustrated in segment 1110. The valve 530 can be open. As
described
herein, the negative pressure source can be run at highest or maximum flow. As
illustrated,
the curve 1104 can be at about 100% duty cycle (for instance, at 95% PW1V1).
Pressure in the
fluid flow path is illustrated by the curve 1102, which shows a steady
pressure at around 35
mmHg. The flow test results can also be used to determine the device health or
negative
pressure source efficiency.
The leak test is illustrated in segment 1120. The valve 530 can be closed. As
described herein, the negative pressure source can be run at low intensity or
low level of
activity. As illustrated by the curve 1104, the negative pressure source can
be pulsed at 20%
PW1VI (or less or more, as described herein). The pulses may be separated by a
delay in time
in order to protect the pressure sensor 532 or 534 from being damaged (such
as, from
establishing high negative pressure in the small volume of the fluid flow path
with the valve
530 closed). As illustrated by the curve 1102, a leak can manifest itself with
a large drop in
the pressure in the fluid flow path. In some cases, the pressure sensor 534
located at the
negative pressure source side of the flow restrictor 540 can be monitored to
determine the
leak.
The excessive pressure test is illustrated by the segment 1130. The valve 530
can be
closed. As described herein, the negative pressure source can be run at low
intensity or low
-37-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
level of activity. As illustrated by the curve 1104, the negative pressure
source can be pulsed
at 20% PWM (or less or more, as described herein). Each pulse can increase the
negative
pressure in the fluid flow path. As described herein, the pulses may be
separated by delays in
time to protect the pressure sensor 532 or 534 from being damaged. At the end
of the
segment 1130, the pressure in the fluid flow path can satisfy the excess
pressure threshold.
Advantageously, self-testing improvements described herein can allow for more
efficient and reliable self-testing of negative pressure devices. This can
shorten negative
pressure wound therapy interruptions and improve patient care.
Other Variations
Although some embodiments describe negative pressure wound therapy, the
systems,
devices, and/or methods disclosed herein can be applied to other types of
therapies usable
standalone or in addition to TNP therapy. Systems, devices, and/or methods
disclosed herein
can be extended to any medical device, and in particular any wound treatment
device. For
example, systems, devices, and/or methods disclosed herein can be used with
devices that
provide one or more of ultrasound therapy, oxygen therapy, neurostimulation,
microwave
therapy, active agents, antibiotics, antimicrobials, or the like. Such devices
can in addition
provide TNP therapy. The systems and methods disclosed herein are not limited
to medical
devices and can be utilized by any electronic device.
Any of the controllers or processors disclosed herein can include electronic
circuitry
(sometimes referred to as control circuity). Electronic circuitry can be
configured to
implement programmable control or hardwired control.
Any value of a threshold, limit, duration, etc. provided herein is not
intended to be
absolute and, thereby, can be approximate. In addition, any threshold, limit,
duration, etc.
provided herein can be fixed or varied either automatically or by a user.
Furthermore, as is
used herein relative terminology such as exceeds, greater than, less than,
etc. in relation to a
reference value is intended to also encompass being equal to the reference
value. For
example, exceeding a reference value that is positive can encompass being
equal to or greater
than the reference value. In addition, as is used herein relative terminology
such as exceeds,
greater than, less than, etc. in relation to a reference value is intended to
also encompass an
-38-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
inverse of the disclosed relationship, such as below, less than, greater than,
etc. in relations to
the reference value.
Features, materials, characteristics, or groups described in conjunction with
a
particular aspect, embodiment, or example are to be understood to be
applicable to any other
aspect, embodiment or example described herein unless incompatible therewith.
All of the
features disclosed in this specification (including any accompanying claims,
abstract and
drawings), and/or all of the steps of any method or process so disclosed, may
be combined in
any combination, except combinations where at least some of such features
and/or steps are
mutually exclusive. The protection is not restricted to the details of any
foregoing
embodiments. The protection extends to any novel one, or any novel
combination, of the
features disclosed in this specification (including any accompanying claims,
abstract and
drawings), or to any novel one, or any novel combination, of the steps of any
method or
process so disclosed.
While certain embodiments have been described, these embodiments have been
presented by way of example only, and are not intended to limit the scope of
protection.
Indeed, the novel methods and systems described herein may be embodied in a
variety of other
forms. Furthermore, various omissions, substitutions and changes in the form
of the methods
and systems described herein may be made. Those skilled in the art will
appreciate that in
some embodiments, the actual steps taken in the processes illustrated and/or
disclosed may
differ from those shown in the figures. Depending on the embodiment, certain
of the steps
described above may be removed, others may be added. For example, the actual
steps and/or
order of steps taken in the disclosed processes may differ from those shown in
the figure.
Depending on the embodiment, certain of the steps described above may be
removed, others
may be added. For instance, the various components illustrated in the figures
or described
herein may be implemented as software and/or firmware on a processor,
controller, ASIC,
FPGA, and/or dedicated hardware. The software or firmware can include
instructions stored
in a non-transitory computer-readable memory. The instructions can be executed
by a
processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components,
such as
controllers, processors, ASICs, FPGAs, and the like, can include logic
circuitry. Furthermore,
the features and attributes of the specific embodiments disclosed above may be
combined in
-39-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
different ways to form additional embodiments, all of which fall within the
scope of the
present disclosure.
User interface screens illustrated and described herein can include additional
and/or
alternative components. These components can include menus, lists, buttons,
text boxes,
labels, radio buttons, scroll bars, sliders, checkboxes, combo boxes, status
bars, dialog boxes,
windows, and the like. User interface screens can include additional and/or
alternative
information. Components can be arranged, grouped, displayed in any suitable
order.
Conditional language used herein, such as, among others, "can," "could",
"might,"
may," "e.g.," and the like, unless specifically stated otherwise, or otherwise
understood
within the context as used, is generally intended to convey that certain
embodiments include,
while other embodiments do not include, certain features, elements and/or
states. Thus, such
conditional language is not generally intended to imply that features,
elements and/or states
are in any way required for one or more embodiments or that one or more
embodiments
necessarily include logic for deciding, with or without author input or
prompting, whether
these features, elements and/or states are included or are to be performed in
any particular
embodiment. The terms "comprising," "including," "having," and the like are
synonymous and
are used inclusively, in an open-ended fashion, and do not exclude additional
elements,
features, acts, operations, and so forth. Also, the term "or" is used in its
inclusive sense (and
not in its exclusive sense) so that when used, for example, to connect a list
of elements, the
term "or" means one, some, or all of the elements in the list. Further, the
term "each," as used
herein, in addition to having its ordinary meaning, can mean any subset of a
set of elements to
which the term "each" is applied. Additionally, the words "herein," "above,"
"below," and
words of similar import, when used in this application, refer to this
application as a whole and
not to any particular portions of this application.
Conjunctive language, such as the phrase "at least one of X, Y and Z," unless
specifically stated otherwise, is to be understood with the context as used in
general to convey
that an item, term, etc. may be either X, Y, or Z, or a combination thereof.
Thus, such
conjunctive language is not generally intended to imply that certain
embodiments require at
least one of X, at least one of Y and at least one of Z to each be present.
-40-
CA 03172080 2022- 9- 16
WO 2021/191203
PCT/EP2021/057425
Language of degree used herein, such as the terms "approximately," "about,"
generally," and "substantially" as used herein represent a value, amount, or
characteristic
close to the stated value, amount, or characteristic that still performs a
desired function or
achieves a desired result For example, the terms "approximately", "about",
"generally," and
"substantially" may refer to an amount that is within less than 10% of, within
less than 5% of,
within less than 1% of, within less than 0.1% of, and within less than 0.01%
of the stated
amount. As another example, in certain embodiments, the terms "generally
parallel" and
"substantially parallel" refer to a value, amount, or characteristic that
departs from exactly
parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3
degrees, 1 degree, or 0.1
degree.
Unless otherwise explicitly stated, articles such as "a" or "an" should
generally be
interpreted to include one or more described items. Accordingly, phrases such
as "a device
configured to" are intended to include one or more recited devices. Such one
or more recited
devices can also be collectively configured to carry out the stated
recitations.
Although the present disclosure includes certain embodiments, examples and
applications, it will be understood by those skilled in the art that the
present disclosure extends
beyond the specifically disclosed embodiments to other alternative embodiments
and/or uses
and obvious modifications and equivalents thereof, including embodiments which
do not
provide all of the features and advantages set forth herein. Accordingly, the
scope of the
present disclosure is not intended to be limited by the specific disclosures
of preferred
embodiments herein, and may be defined by claims as presented herein or as
presented in the
future.
-41 -
CA 03172080 2022- 9- 16
